Wolters Kluwer Agrees to Buy Clinical AI Company AgileMD

Wolters Kluwer Health announced on November 13, 2026, that it had signed an agreement to acquire AgileMD for up to $100 million, a transaction that would add interactive clinical pathways and AI-powered patient-deterioration surveillance to its clinical business.

The consideration consists of a $40 million upfront payment and a deferred balance contingent on performance targets. The transaction is expected to close in the first quarter of 2027 or sooner, subject to customary closing conditions and governmental approvals. It has not yet closed.

AgileMD was founded in 2011 and is based in San Francisco. Its co-founders are CEO Borna Safabakhsh and chief medical officer Dana Edelson, and all 23 employees are expected to join Wolters Kluwer Health.

Two Products for Hospital Workflows

AgileMD’s Pathways product brings a health system’s local guidelines into electronic health record (EHR) workflows. Clinicians can use the pathways to enter orders, align order sets and other decision support, generate documentation, and incorporate laboratory results and vital signs. The product also supports outcomes measurement, putting protocol delivery and subsequent review in the same working environment.

The second product, eCART, is a real-time AI surveillance engine that identifies and prioritizes patients at risk of all-cause clinical deterioration, meaning a worsening in their condition. Wolters Kluwer describes the FDA-cleared product as designed to help care teams escalate treatment and reduce mortality rates.

On AgileMD’s product page, the company says eCART’s analytic was trained and tested on nearly 3 million patient encounters from 28 hospitals across six health systems. Retrospective and prospective validation covered sepsis, COPD, CHF and COVID populations.

AgileMD reports platform totals exceeding 400 hospitals, 150,000 clinical users and 4.425 million patient encounters. More than 4,800 pathways are live at partner institutions, covering adult, pediatric and neonatal topics across ambulatory, emergency, inpatient, intensive-care and women’s health settings. The figures describe both the software’s reach and the amount of protocol content already in clinical use.

UpToDate Expert AI Integration Plans

Wolters Kluwer intends to combine AgileMD with UpToDate Expert AI and its partnerships, extending UpToDate into embedded workflows, local guidelines and new digital health applications. Yaw Fellin, senior vice president of Wolters Kluwer Clinical Solutions, said the acquisition is also meant to help health systems improve patient care and obtain more value from their technology investments.

Safabakhsh said UpToDate’s foundational capabilities would allow AgileMD to “accelerate and streamline the development and maintenance of more advanced clinical pathways for complex clinical decision-making support.”

UpToDate Expert AI was introduced in September 2025. Wolters Kluwer reports that it has since been adopted by more than 2,700 U.S. hospitals and health systems, representing more than 95% of U.S.-based UpToDate Enterprise Edition customers. The acquisition would connect that customer footprint with AgileMD’s pathway and surveillance tools, while the expansion into additional workflows and applications remains a plan ahead of closing.

Revenue and Return Expectations

Wolters Kluwer projects that AgileMD will reach $7 million in annual recurring revenue by the end of 2026 and that the acquisition will achieve a return on invested capital at or above its 8% after-tax weighted average cost of capital within three to five years, with an immaterial effect on adjusted earnings.

For Wolters Kluwer, the strategic value lies in placing guidance and deterioration alerts directly inside clinical workflows. The deferred consideration and return target tie that plan to subsequent performance, while governmental approvals and other closing conditions still stand between the signed agreement and a completed acquisition.